PubMed · 10459260
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
M G Kortepeter, K T McKee. 1999. Disease prevention while deployed.. https://pubmed.ncbi.nlm.nih.gov/10459260/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
BACKGROUND: There are relationships among morbidity experiences before, during, and after participation in overseas military operations. METHODS: U.S. servicemembers who deployed to Bosnia-Herzegovina during a 4-year period were classified based on their last hospitalizations prior to deploying. Hospitalization rates during and following deployment were calculated in relation to the timing and causes of pre-deployment hospitalizations. RESULTS: Deployers ever hospitalized pre-deployment were 120% and 50% more likely to be hospitalized during and following deployment, respectively. For nearly every category of diagnoses, hospitalization rates during and following deployment were highest among those hospitalized for the same category, intermediate among those hospitalized for other categories, and lowest among those not hospitalized prior to deploying. Deployers hospitalized within 1 month, 2-3 months, or > 3 months of deploying were 3.8, 2.6, and 1.4-times more likely to be hospitalized during deployment. CONCLUSIONS: The nature and recency of prior hospitalizations significantly determine during and post-deployment hospitalization risks.
In order to investigate the serological relationship of Dobrava hantavirus (DOBV, originating from Slovenia) and the Dobrava-like Saaremaa virus (SAAV, recently discovered in Estonia) we analysed 37 human serum samples, 24 from Estonia and 13 from the Balkans, by focus reduction neutralization test (FRNT). Most of the Estonian sera (19), including all sera from Saaremaa island (12), reacted with higher FRNT end-point titres to the local SAAV; the majority of them (15 and 11, respectively), with at least fourfold or higher titres to SAAV than to DOBV. In contrast, out of the 13 sera collected in Slovenia, Bosnia-Herzegovina and Greece, only one reacted more strongly with SAAV (with a twofold higher titre), while 10 of these sera reacted more strongly with the local DOBV (9/10 with fourfold or higher titres). These results indicate that DOBV and SAAV define unique hantavirus serotypes.